Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
4Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
Anavex Life Sciences Corp. (AVXL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
2Distinct source URLs
6High confidence
0.788Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Anavex Life Sciences Corp. Suppliers
Ticker
Name
Confidence
Evidence
LIFE-SCIENCE-RESEARCH-ISRAEL-LTD
LIFE-SCIENCE-RESEARCH-ISRAEL-LTD
90%
We are party to an exclusive license agreement with Life Science Research Israel Ltd., with respect to certain in-licensed intellectual property related to our ANAVEX ® 3-71 product candidate
MICHAEL-J-FOX-FOUNDATION-FOR-PARKINSON-S-RESEARC
MICHAEL-J-FOX-FOUNDATION-FOR-PARKINSON-S-RESEARC
90%
The Company had received a $ 1.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson's Research.
Anavex Life Sciences Corp. Customers
Ticker
Name
Confidence
Evidence
ANAVEX-AUSTRALIA-PTY-LIMITED
ANAVEX-AUSTRALIA-PTY-LIMITED
62%
ll disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements a…
ANAVEX-CANADA-LTD
ANAVEX-CANADA-LTD
62%
ll disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements a…
AUSTRALIA-ANAVEX-GERMANY-GMBH
AUSTRALIA-ANAVEX-GERMANY-GMBH
62%
ls to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The Company’s focus is on developing innovativ…
USA-LLC
USA-LLC
62%
ll disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements a…
Anavex Life Sciences Corp. Debt Obligations
Instrument
Description
Confidence
Evidence
AVXL-DEBT
Debt stack $345
90%
Market cache reports total debt of $345.
AVXL-DEBT-8005
Warrants outstanding: 5989900
90%
xbrl warrant detail from xbrl 2021-09-30.
AVXL-DEBT-8006
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2016-09-30.
Anavex Life Sciences Corp. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Anavex Life Sciences Corp..
Anavex Life Sciences Corp. Ownership
Holder
Name
Confidence
Evidence
AVXL-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 194 tracked holders.
Anavex Life Sciences Corp. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
